TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06090643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive CRC screening usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation
Description: Receive consultation with clinic staff

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive education and training on CRC screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test
Description: Receive FIT kit with culturally tailored instructions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Receive feedback on CRC screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive CRC screening recommendations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support Education Activity
Description: Utilize clinical decision support tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive text message reminders
Study: NCT02344290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: One tablet (4 mg) taken once daily, orally with or without food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet taken once daily, orally with or without food
Study: NCT04245215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
Study: NCT04542408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation Agents (Edoxaban and/or high dose LMWH)
Description: In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until

Intervention type: DRUG
Group type: OTHER
Intervention: Low dose Low molecular weight heparin or Placebo
Description: In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
Study: NCT03082833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
Study: NCT01381952

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.
Description: Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Normal dose DSA with conventional X-ray technology
Description: Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
Study: NCT03671733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
Study: NCT01892111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise program.
Study: NCT03671733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Microspheres for Injection
Description: Exenatide 2 mg injection once weekly for 12 weeks.
Study: NCT02919397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Programme educational material
Description: Educational material accessed through smartphone application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational messaging
Description: Messages sent via smartphone application
Study: NCT02643953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: 1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community
Description: 1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
Study: NCT02768077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin(Circadin®)
Study: NCT04451343

Intervention type: OTHER
Intervention: biographical interviews
Description: A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
Study: NCT02768077

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01723514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month
Study: NCT02289287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management group-intervention
Description: At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
Study: NCT02459184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Income Security Health Promotion
Description: The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~* Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~* Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~* Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~* Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Income Security Health Promotion
Description: The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~* Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~* Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~* Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~* Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs.
Study: NCT01630408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol oral capsules 1 mcg/day for 48 weeks
Study: NCT01723514

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month
Study: NCT00989313

Intervention type: DRUG
Intervention: Lesion count
Description: Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Study: NCT01336387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retinoid 9cUAB30
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cancer prevention
Description: Disease prevention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cancer prevention
Description: Disease prevention
Study: NCT03779321

Intervention type: OTHER
Group type: OTHER
Intervention: Acceptability
Description: Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals

Intervention type: OTHER
Group type: OTHER
Intervention: Acceptability
Description: Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
Study: NCT02234635

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffractive multifocal IOLs group
Description: Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.

Intervention type: OTHER
Group type: OTHER
Intervention: Diffractive multifocal IOLs group
Description: Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
Study: NCT02236702

Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) imaging
Description: Positron Emission Tomography (PET) imaging

Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) imaging
Description: Positron Emission Tomography (PET) imaging

Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) imaging
Description: Positron Emission Tomography (PET) imaging

Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) imaging
Description: Positron Emission Tomography (PET) imaging
Study: NCT00919009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE (Transcatheter Arterial Chemoembolization )
Description: TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions
Study: NCT03479359

Intervention type: BEHAVIORAL
Intervention: Routine review of DRE results by attending doctors
Description: Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.
Study: NCT04075097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 1 session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Description: 1 session
Study: NCT01998997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family educational intervention
Description: The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Family educational intervention
Description: The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
Study: NCT04037306

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Butyrate Feedback
Description: Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Butyrate Feedback
Description: Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fiber Feedback
Description: Estimated fiber consumption from menu records of weight loss facility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fiber Feedback
Description: Estimated fiber consumption from menu records of weight loss facility.
Study: NCT01829685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir, Adefovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir, Adefovir
Study: NCT02521025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent feeding pattern
Description: Intermittent feeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous feeding pattern
Description: Continuous feeding
Study: NCT03657537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketone infusion
Description: β-hydroxybutyrate is infused intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketone infusion
Description: β-hydroxybutyrate is infused intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline infusion
Description: saline is infused intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline infusion
Description: saline is infused intravenously.
Study: NCT02391116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
Study: NCT01437384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: 20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
Study: NCT00502983

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview lasting approximately 50 minutes.
Study: NCT02958813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA
Description: Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FUEL
Description: FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
Study: NCT01845558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wobenzym® plus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00812825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets similar in appearance to prednisolone will be administered once daily for 14 days.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo Solution
Description: Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
Study: NCT00937040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS MPH
Description: Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS MPH Tablets
Description: Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
Study: NCT04478513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
Study: NCT02498379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu[64]-25%CANF-Comb
Description: Intravenous injection of 4-8 mCi of Cu\[64\]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
Study: NCT04733196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Study: NCT00812825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327 Tablet
Description: A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
Study: NCT02261285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Study: NCT02947581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole and praziquantel
Description: Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole and praziquantel placebo
Description: PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
Study: NCT01137123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.